Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: Netherlands,France,United Kingdom,Germany,Sweden,Austria,Spain,Portugal,Croatia,Italy
nct
MAJ Il y a 5 ans
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
This study will assess the efficacy and safety of nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive/BCR-ABL positive chronic myeloid leukaemia in chronic phase. The aim of the study is to confirm the rates of complete molecular remission (CMR) of nilotinib in newly diagnosed CML chronic phase patients in a pan-European population using the EUTOS standardized laboratories.
Pays
Austria
,
Belgium
,
Bulgaria
,
Croatia
,
Czech Republic
,
Denmark
,
Estonia
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Italy
,
Latvia
,
Lithuania
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Romania
,
Slovakia
,
Slovenia
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes
Study Objectives: To collect and describe demographics, disease-management, and treatment outcomes of Myelodysplastic Syndromes (MDS) patients who are newly diagnosed and classified according to the WHO criteria. To perform observational studies concerning relevant scientific research questions in MDS using clinical data and biological samples, and to present relevant research outcomes in the fields of diagnosis and prognostication, health related quality of life issues, health economics, and risk stratification for newly developed classes of drugs. To disseminate results of the studies to all stakeholders involved.
Pays
Austria
,
Croatia
,
Czech Republic
,
Denmark
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Netherlands
,
Poland
,
Portugal
,
Romania
,
Serbia
,
Spain
,
Sweden
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai ouvert aux inclusions
Plus d'informations
1